In accordance with ACR pointers, allopurinol is strongly proposed as a first-line urate-decreasing medication. Genetic tests is recommended (for the variant called HLA B*5801) previous to starting allopurinol since the carriers of this gene are at a heightened hazard of a intense allergic response.